Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Oxaliplatin 5Radiotherapy 3Leucovorin 3Irinotecan 3Erlotinib Hydrochloride 3Cetuximab 3Bevacizumab 3selpercatinib 2cediranib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Gemcitabine 2Fluorouracil 2Docetaxel 2ulixertinib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1tanespimycin 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1oblimersen 1motexafin gadolinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Mesothelin × CNS × Clear all
NCT04842812 2024-06-25

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 1 Recruiting
40 enrolled
BreastCNSGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡